tetano
Editor, Senior Moderator
Proc Natl Acad Sci U S A
. 2024 Oct 8;121(41):e2408469121.
doi: 10.1073/pnas.2408469121. Epub 2024 Sep 30. Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections
Imrul Shahriar[SUP] 1 2 [/SUP], Mohini Kamra[SUP] 1 [/SUP], Ananda Kumar Kanduluru[SUP] 1 2 [/SUP], Charity Lynn Campbell[SUP] 1 2 [/SUP], Thanh Hiep Nguyen[SUP] 3 [/SUP], Madduri Srinivasarao[SUP] 1 2 [/SUP], Philip S Low[SUP] 1 [/SUP]
Affiliations
Despite much research, considerable data suggest that influenza virus remains a serious health problem because i) the effectiveness of current vaccines ranges only from 19% to 60%, ii) available therapies remain ineffective in advanced stages of disease, iii) death rates vary between 25,000 and 72,000/year in the United States, and iv) avian influenza strains are now being transmitted to dairy cattle that in turn are infecting humans. To address these concerns, we have developed zanDR, a bispecific small molecule that binds and inhibits viral neuraminidase expressed on both free virus and virus-infected cells and recruits naturally occurring anti-rhamnose and anti-dinitrophenyl (DNP) antibodies with rhamnose and DNP haptens. Because the neuraminidase inhibition replicates the chemotherapeutic mechanism of zanamivir and oseltamivir, while rhamnose and DNP recruit endogenous antibodies much like an anti-influenza vaccine, zanDR reproduces most of the functions of current methods of protection against influenza virus infections. Importantly, studies on cells in culture demonstrate that both of the above protective mechanisms remain highly functional in the zanDR conjugate, while studies in lethally infected mice with advanced-stage disease establish that a single intranasal dose of zanDR not only yields 100% protection but also reduces lung viral loads faster and ~1,000× more thoroughly than current antiviral therapies. Since zanDR also lowers secretion of proinflammatory cytokines and protects against virus-induced damage to the lungs better than current therapies, we suggest that combining an immunotherapy with a chemotherapy in single pharmacological agent constitutes a promising approach for treating the more challenging forms of influenza.
Keywords: antiviral therapeutics; immunotherapy of influenza virus infections; recruitment of antibodies to virus-infected cells.
. 2024 Oct 8;121(41):e2408469121.
doi: 10.1073/pnas.2408469121. Epub 2024 Sep 30. Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections
Imrul Shahriar[SUP] 1 2 [/SUP], Mohini Kamra[SUP] 1 [/SUP], Ananda Kumar Kanduluru[SUP] 1 2 [/SUP], Charity Lynn Campbell[SUP] 1 2 [/SUP], Thanh Hiep Nguyen[SUP] 3 [/SUP], Madduri Srinivasarao[SUP] 1 2 [/SUP], Philip S Low[SUP] 1 [/SUP]
Affiliations
- PMID: 39348541
- DOI: 10.1073/pnas.2408469121
Despite much research, considerable data suggest that influenza virus remains a serious health problem because i) the effectiveness of current vaccines ranges only from 19% to 60%, ii) available therapies remain ineffective in advanced stages of disease, iii) death rates vary between 25,000 and 72,000/year in the United States, and iv) avian influenza strains are now being transmitted to dairy cattle that in turn are infecting humans. To address these concerns, we have developed zanDR, a bispecific small molecule that binds and inhibits viral neuraminidase expressed on both free virus and virus-infected cells and recruits naturally occurring anti-rhamnose and anti-dinitrophenyl (DNP) antibodies with rhamnose and DNP haptens. Because the neuraminidase inhibition replicates the chemotherapeutic mechanism of zanamivir and oseltamivir, while rhamnose and DNP recruit endogenous antibodies much like an anti-influenza vaccine, zanDR reproduces most of the functions of current methods of protection against influenza virus infections. Importantly, studies on cells in culture demonstrate that both of the above protective mechanisms remain highly functional in the zanDR conjugate, while studies in lethally infected mice with advanced-stage disease establish that a single intranasal dose of zanDR not only yields 100% protection but also reduces lung viral loads faster and ~1,000× more thoroughly than current antiviral therapies. Since zanDR also lowers secretion of proinflammatory cytokines and protects against virus-induced damage to the lungs better than current therapies, we suggest that combining an immunotherapy with a chemotherapy in single pharmacological agent constitutes a promising approach for treating the more challenging forms of influenza.
Keywords: antiviral therapeutics; immunotherapy of influenza virus infections; recruitment of antibodies to virus-infected cells.